Patents by Inventor Andrew A. Vaewhongs

Andrew A. Vaewhongs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8729236
    Abstract: Methods to derive novel hybrid type 1 interferons that are broadly active against highly pathogenic viruses of biodefense significance are described. Libraries of hybrid interferon genes were produced using gene shuffling, the proteins were expressed, and screened for activity against viruses of interest. Sequences of several broadly active hybrid interferons are described.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: May 20, 2014
    Inventors: Hal S. Padgett, Fakhrieh S. Vojdani, Andrew A. Vaewhongs
  • Publication number: 20120302733
    Abstract: Methods to derive novel hybrid type 1 interferons that are broadly active against highly pathogenic viruses of biodefense significance are described. Libraries of hybrid interferon genes were produced using gene shuffling, the proteins were expressed, and screened for activity against viruses of interest. Sequences of several broadly active hybrid interferons are described.
    Type: Application
    Filed: May 23, 2012
    Publication date: November 29, 2012
    Inventors: Hal S. Padgett, Fakhrieh S. Vojdani, Andrew A. Vaewhongs
  • Publication number: 20110111413
    Abstract: The present invention relates to codon optimization utilizing DNA shuffling. A method of producing gene sequences optimized for a desired functional property is described involving synthesizing a library of parental codon variant genes encoding some or all codon choices at some or all amino acid positions of a gene, reassorting the variant codons among the parental codon variant genes using DNA shuffling thereby forming progeny codon variant genes, expressing the progeny codon variant genes in a host; and screening or selecting for progeny codon variant genes encoding a desired functional property.
    Type: Application
    Filed: November 23, 2010
    Publication date: May 12, 2011
    Inventors: Hal S. Padgett, John A. Lindbo, Wayne P. Fitzmaurice, Andrew A. Vaewhongs
  • Patent number: 7888475
    Abstract: Herein is described a system to combat poxvirus infection wherein antagonists are developed that bind the soluble cytokine receptor but have no significant biological activity in the host, effectively blocking the virus-mediated suppressor of interferon function, thereby permitting the host's own cytokines to stimulate an antiviral response. Alternatively, interferon molecules can be developed that retain biological activity on their native receptors but fail to bind the viral cytokine binding protein, thereby circumventing this virus immune modulation mechanism.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: February 15, 2011
    Inventors: Hal S. Padgett, Fakhrieh S. Vojdani, Andrew A. Vaewhongs
  • Patent number: 7838219
    Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3? to 5? exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: November 23, 2010
    Assignee: Novici Biotech LLC
    Inventors: Hal S. Padgett, John A. Lindbo, Wayne P. Fitzmaurice, Andrew A. Vaewhongs
  • Publication number: 20100121030
    Abstract: Herein is described a system to combat poxvirus infection wherein antagonists are developed that bind the soluble cytokine receptor but have no significant biological activity in the host, effectively blocking the virus-mediated suppressor of interferon function, thereby permitting the host's own cytokines to stimulate an antiviral response. Alternatively, interferon molecules can be developed that retain biological activity on their native receptors but fail to bind the viral cytokine binding protein, thereby circumventing this virus immune modulation mechanism.
    Type: Application
    Filed: September 15, 2009
    Publication date: May 13, 2010
    Inventors: Hal S. Padgett, Fakhrieh S. Vojdani, Andrew A. Vaewhongs
  • Patent number: 7498480
    Abstract: This invention is directed to a monopartite RNA viral vector comprising modified tobravirus RNA-1 comprising an inserted foreign RNA sequence. This invention is also directed to a bipartite RNA viral vector derived from a tobravirus, wherein the vector comprises one or more foreign RNA sequences. The invention is directed to a method of silencing one or more endogenous plant host genes and a method of simultaneously silencing a plant host gene and expressing a foreign gene in a plant host. Such methods comprise infecting a plant host with a bipartite vector comprising modified tobravirus RNA-1 and RNA-2. The invention is further directed to a method of compiling a plant functional gene profile, a method of changing the phenotype or biochemistry of a plant host, and a method of determining the presence of a trait in a plant host, using a monopartite or bipartite viral vector derived from a tobravirus.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: March 3, 2009
    Assignee: Novici Biotech LLC
    Inventors: Peter D. Roberts, Monto H. Kumagai, Andrew A. Vaewhongs
  • Publication number: 20080145913
    Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3? to 5? exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. Also described are mismatch endonucleases suitable for use in the process.
    Type: Application
    Filed: September 24, 2007
    Publication date: June 19, 2008
    Inventors: Hal S. Padgett, Andrew A. Vaewhongs
  • Patent number: 7273739
    Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3? to 5? exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: September 25, 2007
    Inventors: Hal S. Padgett, Andrew A. Vaewhongs
  • Publication number: 20060194288
    Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3? to 5? exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.
    Type: Application
    Filed: May 3, 2006
    Publication date: August 31, 2006
    Inventors: Hal Padgett, Andrew Vaewhongs
  • Patent number: 7078211
    Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3? to 5? exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: July 18, 2006
    Assignee: Large Scale Biology Corporation
    Inventors: Hal S. Padgett, Andrew A. Vaewhongs
  • Patent number: 7056740
    Abstract: We describe here restriction endonucleases and their uses. Restriction endonucleases are useful in finding single nucleotide polymorphisms. They are also useful in an in vitro method of redistributing sequence variations between non-identical polynucleotide sequences.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: June 6, 2006
    Assignee: Large Scale Biology Corporation
    Inventors: Hal S. Padgett, Andrew A. Vaewhongs, Fakhrieh S. Vojdani, Mark L. Smith, John A. Lindbo, Wayne P. Fitzmaurice
  • Publication number: 20050210543
    Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3? to 5? exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.
    Type: Application
    Filed: March 14, 2005
    Publication date: September 22, 2005
    Applicant: LARGE SCALE BIOLOGY CORPORATION
    Inventors: Hal Padgett, Andrew Vaewhongs, Fakhrieh Vojdani, Mark Smith
  • Publication number: 20040180352
    Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3′ to 5′ exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.
    Type: Application
    Filed: August 8, 2003
    Publication date: September 16, 2004
    Applicant: LARGE SCALE BIOLOGY CORPORATION
    Inventors: Hal S. Padgett, John A. Lindbo, Wayne P. Fitzmaurice, Andrew A. Vaewhongs
  • Publication number: 20040142433
    Abstract: We describe here an in vitro method of redistributing sequence variations between non-identical polynucleotide sequences, by making a heteroduplex polynucleotide from two non-identical polynucleotides; introducing a nick in one strand at or near a base pair mismatch site; removing mismatched base(s) from the mismatch site where the nick occurred; and using the opposite strand as template to replace the removed base(s) with bases that complement base(s) in the first strand. By this method, information is transferred from one strand to the other at sites of mismatch.
    Type: Application
    Filed: October 10, 2003
    Publication date: July 22, 2004
    Inventors: Hal S. Padgett, Wayne P. Fitzmaurice, John A. Lindbo, Andrew A. Vaewhongs, Fakhrieh S. Vojdani, Mark L. Smith
  • Publication number: 20030157495
    Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3′ to 5′ exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.
    Type: Application
    Filed: March 14, 2002
    Publication date: August 21, 2003
    Inventors: Hal S. Padgett, Andrew A. Vaewhongs, Fakhrieh S. Vojdani, Mark L. Smith
  • Publication number: 20030157682
    Abstract: We describe here restriction endonucleases and their uses. Restriction endonucleases are useful in finding single nucleotide polymorphisms. They are also useful in an in vitro method of redistributing sequence variations between non-identical polynucleotide sequences.
    Type: Application
    Filed: January 31, 2003
    Publication date: August 21, 2003
    Inventors: Hal S. Padgett, Andrew A. Vaewhongs, Fakhrieh S. Vojdani, Mark L. Smith, John A. Lindbo, Wayne P. Fitzmaurice
  • Publication number: 20030148315
    Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3′ to 5′ exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.
    Type: Application
    Filed: August 1, 2002
    Publication date: August 7, 2003
    Inventors: Hal S. Padgett, Andrew A. Vaewhongs